Fractyl Health (NASDAQ:GUTS) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Fractyl Health (NASDAQ:GUTS) from a hold rating to a sell rating in a report released on Saturday.

A number of other research analysts have also issued reports on the stock. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a report on Thursday, June 4th. Weiss Ratings lowered shares of Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 6th. Finally, Craig Hallum began coverage on shares of Fractyl Health in a research report on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price target for the company. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $5.12.

Fractyl Health Price Performance

Fractyl Health stock opened at $0.66 on Friday. The company has a current ratio of 3.15, a quick ratio of 3.15 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $105.06 million, a PE ratio of -0.75 and a beta of 2.32. Fractyl Health has a 12 month low of $0.38 and a 12 month high of $2.44. The stock has a 50-day moving average price of $0.76 and a two-hundred day moving average price of $0.65.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Analysts expect that Fractyl Health will post -0.53 EPS for the current year.

Insider Activity

In related news, Director William Bradley acquired 68,493 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The shares were bought at an average cost of $0.73 per share, with a total value of $49,999.89. Following the completion of the purchase, the director directly owned 84,622 shares in the company, valued at $61,774.06. The trade was a 424.66% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ian Sheffield bought 35,000 shares of Fractyl Health stock in a transaction that occurred on Wednesday, June 10th. The stock was bought at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the acquisition, the director directly owned 35,000 shares of the company’s stock, valued at $25,550. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 171,493 shares of company stock valued at $127,150. Insiders own 8.52% of the company’s stock.

Institutional Trading of Fractyl Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GUTS. Bank of America Corp DE raised its holdings in Fractyl Health by 23.5% during the 3rd quarter. Bank of America Corp DE now owns 88,634 shares of the company’s stock worth $141,000 after purchasing an additional 16,856 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Fractyl Health in the 2nd quarter valued at $31,000. Jump Financial LLC bought a new stake in shares of Fractyl Health in the 4th quarter valued at $57,000. FNY Investment Advisers LLC increased its position in shares of Fractyl Health by 84.3% during the second quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company’s stock worth $51,000 after buying an additional 29,920 shares during the period. Finally, Scientech Research LLC acquired a new stake in shares of Fractyl Health during the third quarter worth $49,000.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.